Table 1.
Effect of LCFAs on PPARγ ligand assay and mitochondrial membrane potential variation.
| Treatment | PPARγ bind (mP) | ΔMMP (au) |
|---|---|---|
| Vehicle | 108 ± 9 | 21 ± 1.9 |
| Rosiglitazone (10 μM) | 43 ± 2* | ND |
| CCCP (5 μM) | ND | 6 ± 0.5* |
| Staurosporine (1 μM) | ND | 70 ± 4* |
| Oleic (100 μM) | 109 ± 12 | 21 ± 1.6 |
| Linoleic (100 μM) | 98 ± 10 | 22 ± 0.7 |
| α-Linolenic (100 μM) | 76 ± 8* | 24 ± 0.2 |
| γ-Linolenic (10 μM) | 91 ± 8 | 22 ± 0.7 |
| γ-Linolenic (100 μM) | 71 ± 16* | 22 ± 0.9 |
| AA (100 μM) | 70 ± 8* | 28 ± 1.9* |
| EPA (10 μM) | 89 ± 7 | 23 ± 1,3 |
| EPA (100 μM) | 63 ± 15* | 34 ± 1.3* |
| DHA (10 μM) | 82 ± 7 | 25 ± 0.9 |
| DHA (100 μM) | 56 ± 3* | 38 ± 0.7* |
PPARγ binding was measured by fluorescence polarization and mitochondrial membrane potential variation (ΔMMP) was measured by flow cytometry as Material and Methods section described and was expressed as mP and arbitrary units (au), respectively. Results are expressed as mean ± SEM (n = 3–5). *P < 0.05 versus control group (vehicle). ND, non determined.